#United States #New York #Pomerantz LLP #Soleno Therapeutics #SLNO

Pomerantz Law Firm Investigates Soleno Therapeutics Inc. Amidst Controversy

Overview

Pomerantz LLP has initiated an investigation regarding potential claims against Soleno Therapeutics, Inc., which trades under the symbol SLNO on NASDAQ. This investigation comes in response to alarming reports suggesting possible securities fraud and questionable business practices within the company. Given the recent financial turmoil faced by Soleno, affected investors are being urged to reach out for assistance.

Background

On August 15, 2025, Scorpion Capital released a worrying report on Soleno's only product, Vykat XR, characterizing it as overpriced and possibly unsafe for pediatric use. This assertion alone has raised serious red flags about the company’s operations and transparency concerning product safety and pricing.

The aftermath of this report was felt immediately, as Soleno’s stock saw a significant drop, falling by $5.73 per share—approximately 7.41%, resulting in a closing stock price of $71.63. Such a steep decline within a single trading sessions typically prompts an investigation, especially when associated with allegations of misconduct.

Investigation Details

Pomerantz LLP, a law firm known for its proficient handling of corporate, securities, and antitrust class action litigations, is now stepping in to assess whether Soleno’s executive team, including certain officers and directors, partook in unlawful activities that would mislead investors and manipulate stock prices. The firm has a long-standing reputation for pursuing recourse for victims of financial fraud and has significantly recovered multi-million dollar settlements on behalf of aggrieved investors in the past.

Danielle Peyton, an attorney at Pomerantz, is the point of contact for investors seeking to join potential class action proceedings. She can be contacted via email at [email protected] or by telephone at 646-581-9980 ext. 7980.

Legal Context

In such scenarios for investors, legal representation can be critical in navigating the complexities of class-action lawsuits. The investigation aims to uncover whether investors received accurate information regarding Soleno’s business practices and product claims. The implication is that if substantial evidence of fraud is uncovered, investors could take legal action to hold those responsible accountable and potentially recover losses incurred if they sustained damages due to misleading information.

Firm Background

Founded by Abraham L. Pomerantz, who is recognized as a pioneering figure in the field of class action lawsuits, Pomerantz LLP has litigated numerous high-profile cases over the past 85 years. The firm's commitment to fighting for the rights of those impacted by securities fraud and corporate misconduct is exemplary of its dedication to equity within the business environment.

They boast a presence across several major cities globally, including New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, emphasizing their expansive reach to protect investors. Their stated mission upholds a relentless pursuit of justice, particularly in securities and corporate law matters which affect public shareholders.

Conclusion

The current predicament involving Soleno Therapeutics presents a consequential moment for investors. With allegations of fraud surfacing and a noticeable decline in stock price, stakeholders must remain vigilant. The ongoing investigation by Pomerantz LLP seeks not only to protect investors but also to ensure ethical practices in business—a fundamental pillar of a robust financial market. For those impacted or concerned about their investments in Soleno, reaching out to Pomerantz is a prudent step towards seeking legal clarity and remedy.